Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 12;8:5922. doi: 10.1038/s41598-018-24020-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Changes of cardiac function and left ventricular remodeling measured by different means of imaging examinations, after G-CSF mobilization. (A) Changes of LVEF measured by different means of imaging examinations, from four to eight weeks post-modeling. (A1) Changes of LVEF measured by left ventriculography (LVG). (A2) Changes of LVEF measured by transthoracic echocardiography (TTE). (A3) Changes of LVEF measured by cardiac magnetic resonance imaging (CMR). (A4) Changes of LVEF measured by single photon emission computed tomography (SPECT) ΔLVEF = change of LVEF. (B) Changes of left ventricular diameters and volume measured by TTE and CMR, from four to eight weeks post-modeling. (B1) Changes of left ventricular end-diastolic diameter measured by TTE. (B2) Changes of left ventricular end-diastolic volume measured by CMR. (B3) Changes of change of left ventricular end-systolic diameter measured by TTE. (B4) Changes of left ventricular end-systolic volume measured by CMR ΔLVEDd = change of left ventricular end-diastolic diameter, ΔLVEDV = change of left ventricular end-diastolic volume, ΔLVESd = change of left ventricular end-systolic diameter, and ΔLVESV = change of left ventricular end-systolic volume. CON = control, LOW = low dose group, MID = middle dose group, and HIGH = high dose group. *p < 0.05 compared with control group, ^#p < 0.05 compared with low dose group, and ^$p < 0.05 compared with high dose group. (C) Changes of myocardial infarct and perfusion detect size measured by CMR and SPECT, from four to eight weeks post-modeling. (C1) Changes of myocardial infarct size by CMR. (C2) Changes of myocardial perfusion detect size measured by SPECT CON = control, LOW = low dose group, MID = middle dose group, and HIGH = high dose group. *p < 0.05 compared with control group, ^#p < 0.05 compared with low dose group, and ^$p < 0.05 compared with high dose group. (D) Myocardial viability measured by SPECT, eight weeks post-modeling. CON = control, LOW = low dose group, MID = middle dose group, and HIGH, high dose group. *p < 0.05 compared with control group, ^#p < 0.05 compared with low dose group, and ^Δp < 0.05 compared with high dose group.